<KOREA>
In the second half of last year, the ARB single agent and combination drug market was showing a completely different picture, drawing attention.

After the detection of carcinogenic substances in valsartan generic raw material, that emerged in July 2018, the growth of original drug had been remarkable, but the increased demand completely diminished in the second half of the year.

In particular, ARB+CCB combo market has distinctly different atmospheres in first half and second half. The strength, which was continued until the first half, completely disappeared in the second half.

Twynsta(Boehringer Ingelheim), the largest combo product in the market, recorded sales of 40 billion won, up 7.1% in the first half of the year, but only grew 3.4% between July and November.

Prescriptions of Exforge, which had been enjoying increased demands due to the detection of carcinogenic substances in valsartan generic raw material, rose 20.2% in the first half. However, cumulative prescriptions growth remained only 0.7% in Jul-Nov.

Sevikar(Daiichi Sankyo) also saw slower growth since July, slid to 6.1% versus 8.2% growth in the first half. The growth rate of Telminuvo(Chong Kun Dang Pharmaceutical) down to 7.8% from 20.2%.

In contrast, outpatient prescription market growth rate increased sharply from 4.2% in 1H to 11.1% in 2H.

Since prescriptions of leading products has increased after the dectection of carcinogenic substance in July, the growth rate has changed significantly over one year.

Meanwhile, ARB single agent market was completely different situation. In line with outpatient prescription market, the growth rate increase further in 2H.

Kanarb(Boryung Pharmaceutical), the largest single agent product, saw prescriptions growth by 7.7% in the 1H, soared to 12.1% in the 2H.

In addition, Cozaar(MSD) grew from 4.1% to 5.8%, Atacand(AstraZeneca) grew from 2.3% to 6.9%, Olmetec(Daewoong Pharm) grew from 3.0% to 6.7%, Aprovel(Handok) grew from 0.7% to 5.2%.

However, Diovan(Novartis), which demand had increased the most, prescriptions growth rate slowed down slightly from 9.0% to 8.6%. Micardis(Boehringer Ingelheim) fell from 27.2% to 15.2%.

Edarbi‘s growth rate had dropped from 212.0% to 68.7% with shrinking demands, while Teveten continued to degrow.

In the ARB+CCB+diuretic combination market, SevikarHCT(Daiichi Sankyo)’s prescriptions began to decline in the second quarter.

Amosartan Plus(Hanmi Pharm) and Twotops Plus(Ildong Pharmaceutical) performance remained strong with growth rates above 50%.

Hanki Lee(apple1861@newsmp.com) 다른기사 보기